Inhibitor Economics

References 

1. Ross-Degnan D , Soumerai SB , Avorn J , Bohn RL , Bright R , Aledort LM . Hemophilia home treatment. Economic analysis and implications for health policy . Int J Technol Assess Health Care . 1995;11:327–344
   • MEDLINE
   • CrossRef
2. Gringeri A , Mantovani LG , Scalone L , Mannucci PM  COCIS Study Group . Cost of care and quality of life for patients with hemophilia complicated by inhibitors (The COCIS Study Group) . Blood . 2003;102:2358–2363
   • MEDLINE
   • CrossRef
3. Aledort LM , Cohen M , Hilgartner M , Lipton R . Treatment of hemophiliacs with inhibitors (Cost and effect on blood resources) . In:  Hoyer L editors. Factor VIII Inhibitors . New York, NY: Liss; 1984;p. 353–365
4. Rivard GE , Vick S . Factor VIII inhibitor treatment. Economics of inhibitor treatment in Canada . Semin Hematol . 1994;31(2 suppl 4):41–43
   • MEDLINE
5. Goudemand J . Hemophilia. Treatment of patients with inhibitors (Cost issues) . Haemophilia . 1999;5:397–401
   • MEDLINE
6. Chang H , Sher GD , Blanchette VS , Teitel JM . The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada . Haemophilia . 1999;5:247–252
   • MEDLINE
7. Honda K , Nagao T , Kamiya T , Yoshioka A , Miyazaki T , Takeda T , et al.   Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors [in Japanese] . Rinsho Ketsueki . 1998;39:416–421
   • MEDLINE
8. Bohn RL , Aledort LM , Putnam KG , Ewenstein BM , Mogun H , Avorn J . The economic impact of factor VIII inhibitors in patients with haemophilia . Haemophilia . 2004;10:63–68
   • MEDLINE
9. Gautier P , D’Alche-Gautier MJ , Coatmelec B , Marques-Verdier A , Bertrand MA , Dieval J , et al.   Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors (Experience of six French haemophilia centres) . Haemophilia . 2002;8:674–679
   • MEDLINE
10. Colowick AB , Bohn RL , Avorn J , Ewenstein BM . Immune tolerance induction in hemophilia patients with inhibitors (Costly can be cheaper) . Blood . 2000;96:1698–1702
    • MEDLINE
11. Auerswald G , von Depka Prondzinski M , Ehlken B , Kreuz W , Kurnik K , Lenk H , et al.   Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany . Haemophilia . 2004;10:499–508
    • MEDLINE
12. Knight C , Paisley S , Wight J , Jones ML . Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors . Haemophilia . 2003;9:521–540
    • MEDLINE
13. Chung K , Berger A , Edelsberg J , Neufeld E , Oster J . Cost-effectiveness of FEIBA vs. NovoSeven as initial therapy for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors . Haemophilia . 2004;10(suppl 3):30; (abstr)
14. Hay CR , Baglin TP , Collins PW , Hill FG , Keeling DM . The diagnosis and management of factor VIII and IX inhibitors (A guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO)) . Br J Haematol . 2000;111:78–90
    • MEDLINE
    • CrossRef
15. Berger A , Edelsberg J , Neufeld E , Chung K , Oster G . Cost-effectiveness of FEIBA VH vs NovoSeven as initial therapy for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors . 2004; Presented at the Hemophilia 2004 World Congress, Bangkok Thailand, October 17-21, (abstr 114E)
16. Berntorp E , Donfield S , Waters J , Mattson E , DiMichele D , Gringeri A , et al.   The FEIBA NovoSeven Comparative Study (FENOC)—A randomization evaluation of by-passing agents in hemophilia complicated by inhibitors . Blood . 2005;106:324; (abstr)